Stanford Multiple Sclerosis and Neuroimmunology Program
Antibody testing not recommended to assess immunity for COVID: FDA
National MS Society COVID-19 Information
- What you need to know about COVID-19: Consensus information vetted and published by the National MS Society.
- Guidelines for MS Treatments in the time of COVID-19: Consensus guidelines for the use of disease modifying therapies have been developed by the National Medical Advisory Committee of the National MS Society. These guidelines are listed here.
Stanford Multiple Sclerosis and Neuroimmunology Program Overview
The physicians, nurses, researchers and staff of the Stanford Multiple Sclerosis Neuroimmunology Program are committed to being at the forefront of efforts to understand and treat diseases in which the immune system attacks the body's neurological system. The program is dedicated to the diagnosis, clinical care, and research of multiple sclerosis and treats patients in a holistic interdisciplinary manner that is oriented toward helping patients attain their highest level of well-being. The division is the home to one of the most successful research programs in the world, featuring bench research, translational research and clinical trials in multiple sclerosis and other neuroimmunological disorders.
The Stanford Multiple Sclerosis Center announces "Project BIG," the Brain, Immune and Gut Research Initiative to find the cause and cure of Multiple Sclerosis. Project BIG is designed to overcome the inherent difficulties of discovering the mechanisms of MS by inverting traditional paradigms. Using a broad interdisciplinary collaborative model with a tight interface between clinicians and scientists, Project BIG will seek to identify the patient's unique "immuno-fingerprint" as a step toward the true practice of precision medicine. Nearly one million men and women are afflicted with MS nationally.
Multiple Sclerosis Center Patient Care
Using a collaborative decision-making approach, we work with the patient to find a treatment plan that optimizes his or her disease course and wellness. Our MS specialists and researchers also are involved in a number of studies to understand the MS disease course and improve MS disease management.
Oscar Salvatierra Award
Congratulations to Jeffrey Dunn, MD, inaugural award winner of the Oscar Salvatierra Award for Exceptional Service to Stanford medical students and the Stanford University School of Medicine. Dr. Dunn built the Neurology clerkship into a model of national excellence and the highest rated clerkship in the SOM for more than a decade, inspiring more than a thousand medical students during his tenure.
Stanford MS Center certified by the Consortium of MS Centers
The Stanford Multiple Sclerosis Center was awarded ongoing certification for 2021 as a member Center in good standing with the highly esteemed Consortium of Multiple Sclerosis Centers. Stanford's active membership in the CMSC enables Stanford to continue in its role of national leadership in medical and nursing care in the field of MS.
Welcome to Issue 4 of The BIG Brief — a periodic digest of what is top of mind at Project BIG. As you read through the achievements of the team and the promising research underway, despite all the challenges and hardships of this past year, please consider whether you will renew your support of Project BIG for the 2021 year. Our mission is to unlock the cause and cure for MS and other neurological and autoimmune diseases through a unique clinician-scientist collaboration across disciplines. The BIG Brief provides a snapshot of their worlds as well as a curated collection of articles that have captured our team's attention.
Stanford MS Center Launches COViMS Registry
As a NARCRMS member site, and together with the Consortium of MS Centers (CMSC) and the National MS Society (NMSS), Stanford has joined efforts to launch the COVID-19 Infections in MS & Related Diseases (COViMS) registry. COViMS will capture information on outcomes of people with MS and other CNS demyelinating diseases (Neuromyelitis Optica and MOG antibody disease) who have developed COVID-19 in North America (Canada, Mexico & US). This will help our understanding of this disease and its effects and risks specifically pertaining to our clientele, gathering information which can contribute to a safer tomorrow for the patients we care for.
What we can learn from COVID-19 in kids
Stanford Professor of Neurology & Neurological Sciences, Lawrence Steinman, MD, researches what we can learn from COVID-19 in kids in a new paper published in Proceedings of the National Academy of Sciences.